Allscripts Reports Third Quarter 20... (88 million. This target represents annua...)

Allscripts Reports Third Quarter 2007 Results

Date:11/8/2007

88 million. This target represents annualized growth in total revenue of approximately 25%, and is reflective of approximately 30% annualized growth from software and related services. The Company also updated its GAAP earnings per diluted share outlook to a range of $0.34 to $0.35, representing annualized growth of approximately 55%, and its Non-GAAP adjusted earnings per diluted share outlook to a range of $0.48 to $0.49. Non-GAAP adjusted earnings contemplates the add-back of approximately $6.4 million, or $0.10 per diluted share, of deal-related amortization and approximately $3.0 million, or $0.04 per diluted share, of stock-based compensation, both net of tax.

The Company also provided its outlook for 2008 with annualized growth in total revenue of approximately 20% to 25%, which is reflective of approximately 25% to 30% in annualized growth from software and related services. This target represents annualized growth in GAAP earnings per diluted share of 40% to 50%. Annualized growth in Non-GAAP adjusted earnings per diluted share is expected to be 40% to 45%, which contemplates approximately $6.6 million or $0.10 per diluted share of deal-related amortization, and approximately $6.0 million, or $0.09 per diluted share of stock-based compensation, both net of tax.

Allscripts will conduct a conference call on Thursday, November 8, 2007 at 4:30 PM Eastern Standard Time to discuss the Company's earnings and other information. The conference call can be accessed by dialing 1-888-644-5594 and requesting the Allscripts earnings call, or via the Internet at http://www.allscripts.com. A recording of the conference call will be available for a period of two weeks following the call at http://www.allscripts.com or by calling 1-800-642-1687, ID # 21783504.

Explanation of Non-GAAP Financial Measures

Allscripts reports its financial results in
'/>"/>

SOURCE Allscripts Healthcare Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine news :

1. Allscripts Named to FORTUNE 100 Fastest-Growing Companies List
2. West Penn Allegheny Health System Selects Electronic Health Record From Allscripts
3. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
4. Allscripts Featured in Microsoft HealthVault Worldwide Launch
5. Lakeside Systems Selects Allscripts Electronic Health Record for 100 Physicians
6. Allscripts to Announce Third Quarter 2007 Results on November 8th
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results

Post Your Comments:

(Date:5/21/2013)... (PRWEB) May 21, 2013 MedMar Healing ... drive to benefit Second Harvest Food Bank. Twenty-eight businesses, including ... participate in the food drive. The goal is to raise ... the economic problems facing their families in recent years. ... community and help those in need,” explains Douglas Chloupek of ...

(Date:5/21/2013)... recently published in the New England Journal of ... the University of Colorado School of Medicine finds that ... be used to identify individuals at risk for this ... common variant of the gene for mucin-5B, a protein ... the bronchial tubes. While this variant of the MUC5B ...

(Date:5/21/2013)... Research into genetic features of pulmonary fibrosis by ... of Medicine may lead to improved treatment of this ... by JAMA . , The study found that ... cases of pulmonary fibrosis, a chronic progressive disease with ... of the study, researchers may want to consider including ...

(Date:5/21/2013)... and technological research So Paulo Research Foundation, FAPESP, based ... estimated in US$ 680 million to support 17 Research, ... up to eleven years, subject to continuation reviews on ... the 17 RIDCs will come from FAPESP and the ... infrastructure). Host institutions will participate in a portion of ...

(Date:5/21/2013)... York (PRWEB) May 21, 2013 The ... robot lawsuit is nearing its conclusion in Washington ... Bloomberg.com, during closing statements yesterday, an attorney for the ... the company wanted to tie sales and services for ... the training to keep control of surgeons, to keep ...

Breaking Medicine News(10 mins):Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2 Health News:Researchers find genetic risk factor for pulmonary fibrosis 2 Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2 Health News:Research at the cutting edge of knowledge 2 Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2 Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3 Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4

[0] San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank [0] Researchers find genetic risk factor for pulmonary fibrosis [0] Researchers find genetic tie to improved survival time for pulmonary fibrosis [0] Research at the cutting edge of knowledge [0] Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial

... ... ... ... ...

... ... motorist and developed tinnitus, or severe ringing in her ears; she was granted compensation for ... ... carrier represented by East Tennessee attorney Brack Terry of Terry, Terry & Stapleton ...

... ... than £200 this month because of the cold snap. After one of the coldest Januarys in ... £226 – a £70 hike. , ... February 19, 2010 -- Britons are facing record energy bills of more than £200 this month ...

... Contrast-enhanced magnetic resonance imaging (MRI) may help physicians differentiate ... and wrist enabling more targeted therapies unique to each ... of the American Journal of Roentgenology . Contrast-enhanced ... internal bodily structures. Rheumatoid ...

... ... ... ... ...

MDS Announces Substantial Issuer Bid East Tennessee Attorney Brack Terry Obtains $120,000 Jury Award For Injured Mail Carrier It's Snow Joke as UK Gas and Electricity Bills Hit Record Highs -- Energyhelpline Calls for “Significant” Price Cuts Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis FDA Cancer Drug Approval Rate Highlighted in JNCI 'The Dance' Fundraising Event on February 25th Will Feature Belladiva Show Band; Silent Auction Items Include a Two-Week Condo Stay in New Zealand

(Date:5/21/2013)... , May 21, 2013 Accuray Incorporated ... the publication of study results involving hundreds of ... Radiosurgery System, the most widely used form of ... followed 304 patients for a median of 5 ... found that 97 percent of patients with low-risk ...

(Date:5/21/2013)... Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...

(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...

Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2 New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7 Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2

[0] New Data Validates CyberKnife SBRT for Prostate Cancer Treatment [0] Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients [0] Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference

... N.J., Dec. 15 Synvista Therapeutics, Inc. (NYSE ... dosed the first patient in a 30-patient Phase 2 ... patients with psoriasis. The trial is planned to be ... assess the efficacy of topical SYI-2074, applied twice daily, ...

... DIEGO, Dec. 14 bioTheranostics, a bioMerieux company,that ... in,oncology, reported today findings from three studies using ... of disease recurrence in,individual patients. Data from the ... Breast Cancer Symposium (SABCS). , ...

Cached Medicine Technology:Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis 2 Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis 3 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 2 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 3 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 4

Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Chlamydia pneumoniae Antibodies, IgG & IgM by ELISA Chlamydia Group Antibody, Screen Chimerism, Recipient Pre-Transplant Chenodeoxycholic Acid